Akeso touts Phase 3 wins for two separate inflammatory drugsnews2025-08-25T15:02:31+00:00August 25th, 2025|Endpoints News|
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Themnews2025-08-24T03:39:58+00:00August 24th, 2025|The New York Times|
China’s Biotech Is Cheaper and Faster Than America’snews2025-08-17T05:00:05+00:00August 17th, 2025|The New York Times|
US tariffs could undo generic drugmakers’ efforts to be less reliant on Chinese raw materials, experts saynews2025-08-13T11:00:20+00:00August 13th, 2025|Endpoints News|
Sanofi, Regeneron’s cholesterol drug is in short supply in Chinanews2025-08-12T14:04:43+00:00August 12th, 2025|Endpoints News|
Chinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecificnews2025-08-07T14:19:00+00:00August 7th, 2025|Endpoints News|
Endpoints livestream: What we learned from Q2 earnings about China, tariffs and Trumpnews2025-08-07T11:00:53+00:00August 7th, 2025|Endpoints News|
Sanofi buys China rights to Arrowhead’s lipid drug for $130M upfrontnews2025-08-01T14:47:28+00:00August 1st, 2025|Endpoints News|
FDA chief wants more harmony between CBER and CDERnews2025-07-31T19:48:19+00:00July 31st, 2025|Endpoints News|
Endpoints livestream: Is China’s biotech boom unstoppable?news2025-07-31T14:33:56+00:00July 31st, 2025|Endpoints News|
